December 09, 2016 / 15:17 IST
DIVI has announced in a press release that its Unit-II at Vishakhapatnam (Vizag) has received five observations from the USFDA in a recently concluded inspection (from 29 Nov to 6 Dec). This was a scheduled visit, with the facility’s last inspection in Feb’16 leading to no observations.
ValuationWe currently have a BUY rating on the stock with a Sep’17 TP of Rs 1,400. We await details on the nature of the observations and will accordingly review our rating and price target.
For all recommendations, click here Disclaimer: The views and investment tips expressed by investment experts/broking houses/rating agencies on moneycontrol.com are their own, and not that of the website or its management. Moneycontrol.com advises users to check with certified experts before taking any investment decisions.
Read More
Discover the latest Business News, Sensex, and Nifty updates. Obtain Personal Finance insights, tax queries, and expert opinions on Moneycontrol or download the Moneycontrol App to stay updated!